G1 Therapeutics (NASDAQ:GTHX) Stock Rating Reaffirmed by HC Wainwright

G1 Therapeutics (NASDAQ:GTHX)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research report issued on Thursday, Benzinga reports. They currently have a $9.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 106.42% from the stock’s current price.

Several other research analysts also recently issued reports on GTHX. Wedbush reaffirmed an “outperform” rating and set a $5.00 price objective (up previously from $4.00) on shares of G1 Therapeutics in a report on Wednesday, February 28th. Needham & Company LLC restated a “buy” rating and issued a $12.00 price target on shares of G1 Therapeutics in a research report on Wednesday.

G1 Therapeutics Trading Up 5.6 %

NASDAQ:GTHX traded up $0.23 during trading hours on Thursday, hitting $4.36. 512,912 shares of the stock were exchanged, compared to its average volume of 1,252,248. The company’s 50 day moving average is $3.85 and its two-hundred day moving average is $3.05. G1 Therapeutics has a twelve month low of $1.08 and a twelve month high of $5.00. The company has a quick ratio of 3.45, a current ratio of 3.87 and a debt-to-equity ratio of 1.46. The company has a market capitalization of $228.07 million, a P/E ratio of -4.57 and a beta of 1.71.

G1 Therapeutics (NASDAQ:GTHX) last posted its quarterly earnings data on Wednesday, May 1st. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.01). G1 Therapeutics had a negative return on equity of 106.04% and a negative net margin of 58.13%. The firm had revenue of $14.48 million for the quarter, compared to analyst estimates of $15.21 million. During the same period in the prior year, the company posted ($0.53) EPS. On average, sell-side analysts anticipate that G1 Therapeutics will post -0.64 earnings per share for the current fiscal year.

Insider Buying and Selling

In other G1 Therapeutics news, insider Rajesh Malik sold 28,600 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $4.62, for a total value of $132,132.00. Following the completion of the sale, the insider now owns 169,938 shares of the company’s stock, valued at $785,113.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 8.23% of the stock is owned by insiders.

Institutional Investors Weigh In On G1 Therapeutics

Several large investors have recently modified their holdings of GTHX. Creative Financial Designs Inc. ADV grew its position in shares of G1 Therapeutics by 98.1% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 35,280 shares of the company’s stock valued at $108,000 after purchasing an additional 17,475 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of G1 Therapeutics by 68.3% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 204,200 shares of the company’s stock valued at $294,000 after buying an additional 82,879 shares during the period. Acadian Asset Management LLC bought a new stake in shares of G1 Therapeutics during the third quarter worth $189,000. abrdn plc acquired a new stake in shares of G1 Therapeutics during the fourth quarter worth $1,293,000. Finally, Algert Global LLC bought a new stake in G1 Therapeutics in the 3rd quarter valued at $98,000. 24.21% of the stock is currently owned by institutional investors.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.